Our Services
Medical Information
Helpful Resources
Published on: 9/24/2026
Side effects reported with Genglycos can range from mild and temporary to serious, and may include digestive upset such as nausea, stomach discomfort, or changes in bowel habits, along with headache, dizziness, or skin reactions in some people. Less common but more concerning reactions can involve allergic symptoms, unusual fatigue, or changes in blood sugar levels, which may require prompt medical attention. Your dose, other medications, age, and underlying conditions all influence which effects you may experience and how long they last, so there are several important factors to consider before assuming a symptom is harmless. See below for the complete answer, including which reactions typically fade on their own and which ones warrant contacting a clinician right away.
If you are noticing symptoms and are unsure whether they are a normal medication effect or a sign of something else, a free, instant, online symptom check can help you organize what you are feeling, see possible explanations, and understand whether self-care, a pharmacist conversation, or urgent care is the smartest next step.
Last reviewed for medical accuracy: 09/24/2026
Genglycos is an aminoglycoside-class antibiotic often used to treat serious Gram-negative infections. Like all powerful medications, it can cause side effects. Below is a balanced overview of what to watch for—presented in clear, everyday language. If you ever feel something is wrong, consider doing a free, online symptom check, using the doctor approved Ubie Symptom Checker and always speak to a doctor about anything that could be life-threatening or serious.
Genglycos binds to bacterial ribosomes, disrupting protein synthesis and killing susceptible bacteria. It’s usually reserved for hospital settings or tough infections because of its potency and potential toxicity.
Most people tolerate Genglycos fairly well in the short term. These side effects often show up in 1–10% of patients:
In many cases, basic monitoring (blood tests and vital signs) helps catch and manage these quickly.
Though less common, these adverse effects require immediate attention:
Certain factors can raise your chances of side effects:
If you fall into any of these categories, your doctor will likely adjust the dose and increase monitoring.
Stay alert for any new or worsening symptoms:
Kidney warning signs
Ear and balance warning signs
Breathing or muscle trouble
Allergic reaction
If you notice any of these, seek medical help right away.
You and your care team can work together to minimize side effects:
Genglycos can be a lifesaver against tough infections. In most hospital protocols, its use is carefully managed:
This approach helps you get the full antibacterial punch while keeping side effects in check.
According to prescribing information and reviews in reputable journals, the most common severe issue is kidney injury—seen in about 5–10% of cases without preventive measures. Ototoxicity rates vary but can be as high as 20% in older adults or patients with preexisting ear problems. Your care team will weigh these numbers against the severity of your infection.
If you’re ever unsure whether a new symptom is drug-related, don’t guess. Try a free, online symptom check, using the doctor approved Ubie Symptom Checker for guidance on urgency and possible causes. It’s a quick way to get clarity before you call your doctor or head to the ER.
No matter how experienced your medical team is, your input matters. If anything feels off, trust your instincts: do a symptom check, reach out to your provider, and never hesitate to seek help for potentially life-threatening reactions.
(References)
* Martínez-Carranza M, Blasco P, Gustafsson R, Dong M, Berntsson RP, Widmalm G, Stenmark P. Synaptotagmin Binding to Botulinum Neurotoxins. Biochemistry. 2020 Feb 4;59(4):491-498. doi: 10.1021/acs.biochem.9b00554. Epub 2019 Dec 18. PMID: 31809018.
* Moghimi B, Muthugounder S, Jambon S, Tibbetts R, Hung L, Bassiri H, Hogarty MD, Barrett DM, Shimada H, Asgharzadeh S. Preclinical assessment of the efficacy and specificity of GD2-B7H3 SynNotch CAR-T in metastatic neuroblastoma. Nat Commun. 2021 Jan 21;12(1):511. doi: 10.1038/s41467-020-20785-x. Epub 2021 Jan 21. PMID: 33479234; PMCID: PMC7820416.
* Majzner RG, Ramakrishna S, Yeom KW, Patel S, Chinnasamy H, Schultz LM, Richards RM, Jiang L, Barsan V, Mancusi R, Geraghty AC, Good Z, Mochizuki AY, Gillespie SM, Toland AMS, Mahdi J, Reschke A, Nie EH, Chau IJ, Rotiroti MC, Mount CW, Baggott C, Mavroukakis S, Egeler E, Moon J, Erickson C, Green S, Kunicki M, Fujimoto M, Ehlinger Z, Reynolds W, Kurra S, Warren KE, Prabhu S, Vogel H, Rasmussen L, Cornell TT, Partap S, Fisher PG, Campen CJ, Filbin MG, Grant G, Sahaf B, Davis KL, Feldman SA, Mackall CL, Monje M. GD2-CAR T cell therapy for H3K27M-mutated diffuse midline gliomas. Nature. 2022 Mar;603(7903):934-941. doi: 10.1038/s41586-022-04489-4. Epub 2022 Feb 7. PMID: 35130560; PMCID: PMC8967714.
* Sgambati E, Tani A, Leri M, Delfino G, Zecchi-Orlandini S, Bucciantini M, Nosi D. Correlation between Sialylation Status and Cell Susceptibility to Amyloid Toxicity. Cells. 2022 Feb 9;11(4). doi: 10.3390/cells11040601. Epub 2022 Feb 9. PMID: 35203252; PMCID: PMC8870280.
* Zhang DY, Wang J, Fleeman RM, Kuhn MK, Swulius MT, Proctor EA, Dokholyan NV. Monosialotetrahexosylganglioside Promotes Early Aβ42 Oligomer Formation and Maintenance. ACS Chem Neurosci. 2022 Jul 6;13(13):1979-1991. doi: 10.1021/acschemneuro.2c00221. Epub 2022 Jun 17. PMID: 35713284; PMCID: PMC10137048.
* Del Bufalo F, De Angelis B, Caruana I, Del Baldo G, De Ioris MA, Serra A, Mastronuzzi A, Cefalo MG, Pagliara D, Amicucci M, Li Pira G, Leone G, Bertaina V, Sinibaldi M, Di Cecca S, Guercio M, Abbaszadeh Z, Iaffaldano L, Gunetti M, Iacovelli S, Bugianesi R, Macchia S, Algeri M, Merli P, Galaverna F, Abbas R, Garganese MC, Villani MF, Colafati GS, Bonetti F, Rabusin M, Perruccio K, Folsi V, Quintarelli C, Locatelli F, Precision Medicine Team–IRCCS Ospedale Pediatrico Bambino Gesù. GD2-CART01 for Relapsed or Refractory High-Risk Neuroblastoma. N Engl J Med. 2023 Apr 6;388(14):1284-1295. doi: 10.1056/NEJMoa2210859. PMID: 37018492.
* Ciccone R, Quintarelli C, Camera A, Pezzella M, Caruso S, Manni S, Ottaviani A, Guercio M, Del Bufalo F, Quadraccia MC, Orlando D, Di Cecca S, Sinibaldi M, Aurigemma M, Iaffaldano L, Sarcinelli A, D'Amore ML, Ceccarelli M, Nazio F, Marabitti V, Giorda E, Pezzullo M, De Stefanis C, Carai A, Rossi S, Alaggio R, Del Baldo G, Becilli M, Mastronuzzi A, De Angelis B, Locatelli F. GD2-Targeting CAR T-cell Therapy for Patients with GD2+ Medulloblastoma. Clin Cancer Res. 2024 Jun 3;30(11):2545-2557. doi: 10.1158/1078-0432.CCR-23-1880. PMID: 38551501; PMCID: PMC11145172.
* Lin FY, Stuckert A, Tat C, White M, Ruggieri L, Zhang H, Mehta B, Lapteva N, Mei Z, Major A, Thakkar S, Shum T, Parikh K, Wu MF, Lindsay HB, Scherer L, Shekar M, Baxter P, Wang T, Grilley B, Moeller K, Hicks J, Roy A, Anastas J, Malbari F, Aldave G, Chintagumpala M, Blaney S, Parsons DW, Brenner MK, Heslop HE, Rooney CM, Omer B. Phase I Trial of GD2.CART Cells Augmented With Constitutive Interleukin-7 Receptor for Treatment of High-Grade Pediatric CNS Tumors. J Clin Oncol. 2024 Aug 10;42(23):2769-2779. doi: 10.1200/JCO.23.02019. Epub 2024 May 21. PMID: 38771986; PMCID: PMC11305939.
* Wei W, Fader ME, Kushner BH, Cardenas FI, Kramer K, Basu E, Modak S. Pulmonary Toxicity Associated With Concurrent Lorlatinib and Anti-GD2 Monoclonal Antibody Therapy in Patients With Neuroblastoma. Pediatr Blood Cancer. 2025 Sep;72(9):e31845. doi: 10.1002/pbc.31845. Epub 2025 Jun 23. PMID: 40551396; PMCID: PMC12558605.
* Rosenkrans ZT, Erbe AK, Clemons NB, Feils AS, Medina-Guevara Y, Jeffery JJ, Barnhart TE, Engle JW, Sondel PM, Hernandez R. ImmunoPET Demonstrates that Co-Targeting GD2 and B7-H3 with Bispecific Antibodies Enhances Tumor Selectivity in Preclinical Melanoma Models. Bioconjug Chem. 2025 Aug 20;36(8):1595-1603. doi: 10.1021/acs.bioconjchem.5c00016. Epub 2025 Jul 31. PMID: 40741919.
We would love to help them too.
For First Time Users
We provide a database of explanations from real doctors on a range of medical topics. Get started by exploring our library of questions and topics you want to learn more about.
Was this page helpful?
Purpose and positioning of servicesUbie Doctor's Note is a service for informational purposes. The provision of information by physicians, medical professionals, etc. is not a medical treatment. If medical treatment is required, please consult your doctor or medical institution. We strive to provide reliable and accurate information, but we do not guarantee the completeness of the content. If you find any errors in the information, please contact us.